Oxford BioDynamics Plc
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more
Oxford BioDynamics Plc (OXBOF) - Net Assets
Latest net assets as of September 2025: $1.50 Million USD
Based on the latest financial reports, Oxford BioDynamics Plc (OXBOF) has net assets worth $1.50 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.87 Million) and total liabilities ($9.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.50 Million |
| % of Total Assets | 13.8% |
| Annual Growth Rate | -5.45% |
| 5-Year Change | -77.59% |
| 10-Year Change | -80.63% |
| Growth Volatility | 62.91 |
Oxford BioDynamics Plc - Net Assets Trend (2013–2025)
This chart illustrates how Oxford BioDynamics Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oxford BioDynamics Plc (2013–2025)
The table below shows the annual net assets of Oxford BioDynamics Plc from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $1.50 Million | -65.58% |
| 2024-09-30 | $4.36 Million | -28.03% |
| 2023-09-30 | $6.05 Million | +133.96% |
| 2022-09-30 | $2.59 Million | -61.33% |
| 2021-09-30 | $6.69 Million | -50.72% |
| 2020-09-30 | $13.58 Million | -22.81% |
| 2019-09-30 | $17.59 Million | -12.24% |
| 2018-09-30 | $20.05 Million | +72.91% |
| 2017-09-30 | $11.60 Million | +49.75% |
| 2016-09-30 | $7.74 Million | -14.37% |
| 2015-09-30 | $9.04 Million | +72.72% |
| 2014-09-30 | $5.24 Million | +78.18% |
| 2013-09-30 | $2.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oxford BioDynamics Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6454556900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.49 Million | 432.89% |
| Other Comprehensive Income | $4.13 Million | 275.54% |
| Other Components | $61.00 Million | 4066.22% |
| Total Equity | $1.50 Million | 100.00% |
Oxford BioDynamics Plc Competitors by Market Cap
The table below lists competitors of Oxford BioDynamics Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SIGMATRON INTL DL-01
F:SG3
|
$12.26 Million |
|
AGX Group Berhad
KLSE:0299
|
$12.26 Million |
|
NUTRIBAND INC. DL -001
F:9WV
|
$12.26 Million |
|
Nordicus Partners Corporation
OTCQB:NORD
|
$12.27 Million |
|
Mount Ridley Mines Ltd
AU:MRD
|
$12.26 Million |
|
Nam Hwa Construction Co.Ltd
KQ:091590
|
$12.26 Million |
|
TWay Holdings
KO:004870
|
$12.25 Million |
|
Inch Kenneth Kajang Rubber PLC
KLSE:2607
|
$12.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oxford BioDynamics Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,358,000 to 1,500,127, a change of -2,857,873 (-65.6%).
- Net loss of 14,991,862 reduced equity.
- New share issuances of 7,440,000 increased equity.
- Other comprehensive income increased equity by 924,416.
- Other factors increased equity by 3,769,573.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.99 Million | -999.37% |
| Share Issuances | $7.44 Million | +495.96% |
| Other Comprehensive Income | $924.42K | +61.62% |
| Other Changes | $3.77 Million | +251.28% |
| Total Change | $- | -65.58% |
Book Value vs Market Value Analysis
This analysis compares Oxford BioDynamics Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.02x to 3.70x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-09-30 | $0.23 | $0.00 | x |
| 2014-09-30 | $0.41 | $0.00 | x |
| 2015-09-30 | $0.10 | $0.00 | x |
| 2016-09-30 | $0.09 | $0.00 | x |
| 2017-09-30 | $0.14 | $0.00 | x |
| 2018-09-30 | $0.23 | $0.00 | x |
| 2019-09-30 | $0.19 | $0.00 | x |
| 2020-09-30 | $0.15 | $0.00 | x |
| 2021-09-30 | $0.07 | $0.00 | x |
| 2022-09-30 | $0.03 | $0.00 | x |
| 2023-09-30 | $0.04 | $0.00 | x |
| 2024-09-30 | $0.02 | $0.00 | x |
| 2025-09-30 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oxford BioDynamics Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -999.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1369.12%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 7.25x
- Recent ROE (-999.37%) is below the historical average (-152.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -36.12% | -301.43% | 0.10x | 1.23x | $-1.35 Million |
| 2014 | -14.10% | -111.68% | 0.11x | 1.18x | $-1.26 Million |
| 2015 | -11.13% | -143.16% | 0.07x | 1.08x | $-1.91 Million |
| 2016 | -22.40% | -158.57% | 0.12x | 1.17x | $-2.50 Million |
| 2017 | -32.86% | -321.56% | 0.09x | 1.10x | $-4.96 Million |
| 2018 | -9.75% | -164.67% | 0.06x | 1.05x | $-3.96 Million |
| 2019 | -15.93% | -308.71% | 0.05x | 1.07x | $-4.56 Million |
| 2020 | -31.80% | -945.83% | 0.03x | 1.13x | $-5.67 Million |
| 2021 | -100.09% | -1959.53% | 0.02x | 2.30x | $-7.35 Million |
| 2022 | -259.27% | -4357.14% | 0.01x | 4.38x | $-6.97 Million |
| 2023 | -178.79% | -2122.75% | 0.03x | 2.66x | $-11.43 Million |
| 2024 | -265.42% | -1818.71% | 0.05x | 2.78x | $-12.00 Million |
| 2025 | -999.37% | -1369.12% | 0.10x | 7.25x | $-15.14 Million |
Industry Comparison
This section compares Oxford BioDynamics Plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oxford BioDynamics Plc (OXBOF) | $1.50 Million | -36.12% | 6.25x | $12.26 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |